INGA

Lead Participant: ATDBIO LIMITED

Abstract

Flexmers are next generation aptamers and provide a novel alternative to drug compounds. To enable a very quick and efficient process for flexmer development, ATDBio and Biaffin will combine their expertise to create an integrated drug discovery pipeline for flexmers.

Lead Participant

Project Cost

Grant Offer

 

Participant

ATDBIO LIMITED

Publications

10 25 50